BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Dehghani B, Hashempour T, Hasanshahi Z, Moayedi J. Bioinformatics Analysis of Domain 1 of HCV-Core Protein: Iran. Int J Pept Res Ther 2020;26:303-20. [PMID: 32435167 DOI: 10.1007/s10989-019-09838-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 3] [Article Influence: 2.3] [Reference Citation Analysis]
Number Citing Articles
1 Hasanshahi Z, Hashempour A, Ghasabi F, Moayedi J, Musavi Z, Dehghani B, Sharafi H, Joulaei H. First report on molecular docking analysis and drug resistance substitutions to approved HCV NS5A and NS5B inhibitors amongst Iranian patients. BMC Gastroenterol 2021;21:443. [PMID: 34819046 DOI: 10.1186/s12876-021-01988-y] [Reference Citation Analysis]
2 Jansons J, Skrastina D, Kurlanda A, Petkov S, Avdoshina D, Kuzmenko Y, Krotova O, Trofimova O, Gordeychuk I, Sominskaya I, Isaguliants M. Reciprocal Inhibition of Immunogenic Performance in Mice of Two Potent DNA Immunogens Targeting HCV-Related Liver Cancer. Microorganisms 2021;9:1073. [PMID: 34067686 DOI: 10.3390/microorganisms9051073] [Reference Citation Analysis]
3 Oladipo EK, Ajayi AF, Onile OS, Ariyo OE, Jimah EM, Ezediuno LO, Adebayo OI, Adebayo ET, Odeyemi AN, Oyeleke MO, Oyewole MP, Oguntomi AS, Akindiya OE, Aremu VO, Aboderin DO, Oloke JK. Designing a conserved peptide-based subunit vaccine against SARS-CoV-2 using immunoinformatics approach. In Silico Pharmacol 2021;9:8. [PMID: 33425647 DOI: 10.1007/s40203-020-00062-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Hashempour T, Dehghani B, Musavi Z, Moayedi J, Hasanshahi Z, Sarvari J, Hosseini SY, Hosseini E, Moeini M, Merat S. Impact of IL28 Genotypes and Modeling the Interactions of HCV Core Protein on Treatment of Hepatitis C. Interdiscip Sci 2020;12:424-37. [PMID: 32656614 DOI: 10.1007/s12539-020-00382-8] [Reference Citation Analysis]
5 Dehghani B, Hasanshahi Z, Hashempour T. HIV Capsid and Protease, New Targets of Melittin. Int J Pept Res Ther 2020;26:2057-65. [DOI: 10.1007/s10989-019-10002-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
6 Hashempour T, Dehghani B, Mousavi Z, Yahaghi M, Hasanshahi Z, Moayedi J, Akbari T, Davarpanah MA. Evaluating Drug Resistant Mutations to HCV NS3 Protease Inhibitors in Iranian Naïve Patients. Int J Pept Res Ther 2020;26:1699-710. [DOI: 10.1007/s10989-019-09957-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]